On Aug. 21, 1992, the Food and Drug Administration (FDA) approved licensure of a second DTaP product, prepared and distributed as Tripedia\T by Connaught Laboratories  (Swiftwater, Pennsylvania).

As with ACEL-IMUNE\T, Tripedia\T was licensed only for use as the fourth and/or fifth dose(s) for children aged 15 months through 6 years who had previously been vaccinated against diphtheria, tetanus, and pertussis with three doses of whole-cell diphtheria and tetanus toxoids and pertussis vaccine (DTP).